Glaukos announces iStent study results
Glaukos Corporation announced that, according to a study published in Clinical Ophthalmology, implantation of one, two or three iStent Trabecular Micro-Bypass Stents achieved mean unmedicated intraocular pressure, or IOP reductions of 30%, 37% and 43%, respectively, at 36 months postoperative. In this prospective, randomized study conducted by multiple surgeons at a single investigational site, 119 open-angle glaucoma, or OAG, subjects with preoperative unmedicated IOP of 22 mmHg to 38 mmHg received one, two or three iStents in a standalone procedure. At approximately 36 months postoperative, the one-, two- and three-stent groups achieved unmedicated mean IOP of 17.4 mmHg, 15.8 mmHg and 14.2 mmHg, respectively, compared to preoperative unmedicated mean IOP of 25.0 mmHg for the one- and two-stent groups and 25.1 mmHg for the three-stent group. At 42 months, 61%, 91% and 91% of eyes in the one-, two- and three-stent groups, respectively, achieved a =20% reduction in IOP without medication. According to the study authors, no intraoperative or perioperative complications were reported. During 42 months of postoperative follow-up, the most commonly reported adverse event was progression of pre-existing cataract. However, no eyes required additional glaucoma surgery.